enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Recommendation of "Buy" from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $23.29.

Several equities research analysts recently issued reports on ENGN shares. HC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of enGene in a research note on Tuesday, March 11th. JMP Securities reissued a "market outperform" rating and set a $18.00 price objective on shares of enGene in a research note on Tuesday, April 29th. Finally, Morgan Stanley dropped their price objective on enGene from $37.00 to $34.00 and set an "overweight" rating for the company in a research note on Tuesday, March 11th.

Institutional Investors Weigh In On enGene

Several hedge funds have recently added to or reduced their stakes in ENGN. Blue Owl Capital Holdings LP lifted its stake in enGene by 3.3% during the fourth quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock worth $21,014,000 after purchasing an additional 101,006 shares during the last quarter. Jane Street Group LLC bought a new stake in enGene during the fourth quarter worth about $93,000. Cubist Systematic Strategies LLC lifted its stake in enGene by 15.7% during the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock worth $102,000 after purchasing an additional 2,080 shares during the last quarter. Corton Capital Inc. bought a new stake in enGene during the fourth quarter worth about $157,000. Finally, Deep Track Capital LP lifted its stake in enGene by 74.8% during the fourth quarter. Deep Track Capital LP now owns 4,557,575 shares of the company's stock worth $30,308,000 after purchasing an additional 1,949,942 shares during the last quarter. Institutional investors own 64.16% of the company's stock.

enGene Price Performance

Shares of NASDAQ ENGN opened at $3.02 on Tuesday. The stock has a market cap of $154.32 million, a PE ratio of -1.83 and a beta of -0.40. enGene has a fifty-two week low of $2.65 and a fifty-two week high of $11.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 12.66 and a current ratio of 12.66. The stock has a fifty day moving average of $3.69 and a 200-day moving average of $5.22.

enGene (NASDAQ:ENGN - Get Free Report) last announced its quarterly earnings results on Tuesday, June 10th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.03). Equities research analysts anticipate that enGene will post -1.56 earnings per share for the current year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.